CA2904853A1 - Ablative immunotherapy - Google Patents
Ablative immunotherapy Download PDFInfo
- Publication number
- CA2904853A1 CA2904853A1 CA2904853A CA2904853A CA2904853A1 CA 2904853 A1 CA2904853 A1 CA 2904853A1 CA 2904853 A CA2904853 A CA 2904853A CA 2904853 A CA2904853 A CA 2904853A CA 2904853 A1 CA2904853 A1 CA 2904853A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- tumor
- antigens
- pathogen
- allogeneic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000009169 immunotherapy Methods 0.000 title abstract description 13
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 110
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 99
- 244000052769 pathogen Species 0.000 claims abstract description 55
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 50
- 230000036039 immunity Effects 0.000 claims abstract description 45
- 238000011065 in-situ storage Methods 0.000 claims abstract description 41
- 230000037452 priming Effects 0.000 claims abstract description 40
- 238000002679 ablation Methods 0.000 claims abstract description 35
- 230000017074 necrotic cell death Effects 0.000 claims abstract description 24
- 238000004520 electroporation Methods 0.000 claims abstract description 12
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 171
- 239000000427 antigen Substances 0.000 claims description 78
- 108091007433 antigens Proteins 0.000 claims description 78
- 102000036639 antigens Human genes 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 73
- 230000028993 immune response Effects 0.000 claims description 25
- 210000000987 immune system Anatomy 0.000 claims description 25
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- 206010028851 Necrosis Diseases 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 16
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 230000035800 maturation Effects 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 230000002223 anti-pathogen Effects 0.000 claims description 11
- 230000000259 anti-tumor effect Effects 0.000 claims description 11
- 230000006054 immunological memory Effects 0.000 claims description 10
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 8
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 6
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000033289 adaptive immune response Effects 0.000 claims description 5
- 230000001338 necrotic effect Effects 0.000 claims description 5
- 108010029697 CD40 Ligand Proteins 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims description 3
- 108700012411 TNFSF10 Proteins 0.000 claims description 3
- 206010054094 Tumour necrosis Diseases 0.000 claims description 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 abstract description 14
- 230000003902 lesion Effects 0.000 abstract description 11
- 230000002427 irreversible effect Effects 0.000 abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 6
- 238000000315 cryotherapy Methods 0.000 abstract description 6
- 230000007246 mechanism Effects 0.000 abstract description 5
- 238000002512 chemotherapy Methods 0.000 abstract description 4
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 230000006907 apoptotic process Effects 0.000 abstract description 3
- 238000001959 radiotherapy Methods 0.000 abstract description 3
- 238000002604 ultrasonography Methods 0.000 abstract description 3
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 238000011293 immunotherapeutic strategy Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 57
- 230000000890 antigenic effect Effects 0.000 description 35
- 210000004443 dendritic cell Anatomy 0.000 description 26
- 230000004044 response Effects 0.000 description 23
- 239000000463 material Substances 0.000 description 20
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 14
- 230000034994 death Effects 0.000 description 13
- 230000015654 memory Effects 0.000 description 13
- 238000001802 infusion Methods 0.000 description 11
- 239000002102 nanobead Substances 0.000 description 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108010006519 Molecular Chaperones Proteins 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 102000005431 Molecular Chaperones Human genes 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 230000005951 type IV hypersensitivity Effects 0.000 description 7
- 208000035473 Communicable disease Diseases 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000961 alloantigen Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000037816 tissue injury Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000004721 adaptive immunity Effects 0.000 description 4
- 210000004970 cd4 cell Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000002681 cryosurgery Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 208000013435 necrotic lesion Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000019432 tissue death Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- PVNJLUVGTFULAE-UHFFFAOYSA-N [NH4+].[Cl-].[K] Chemical compound [NH4+].[Cl-].[K] PVNJLUVGTFULAE-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000011129 allogeneic cell therapy Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The disclosure herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues. The immunotherapy relates to first priming patients with allogeneic cells designed to be rejected by a Thl mediated mechanism, then inducing in situ necrosis or apoptosis in a tumor or pathogen infected lesion. Necrosis or apoptosis can be induced by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue. One or more doses of allogeneic cells (e.g., Thl cells) are then delivered within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen.
Description
ABLATIVE IMMUNOTHERAPY
FIELD
[0001] The present disclosure relates generally to immunotherapy and, more specifically, to therapeutic methods and compositions for treating tumors and pathogen infected tissues.
BACKGROUND
FIELD
[0001] The present disclosure relates generally to immunotherapy and, more specifically, to therapeutic methods and compositions for treating tumors and pathogen infected tissues.
BACKGROUND
[0002] Harnessing the power of the immune system to treat chronic infectious diseases or cancer is a major goal of immunotherapy. Active immunotherapy treatments are methods designed to activate the immune system to specifically recognize and destroy tumor or pathogen-infected cells. For over 200 years active immunotherapy approaches have been used to prevent numerous infectious diseases, including small pox, rabies, typhoid, cholera, plague, measles, varicella, mumps, poliomyelitis, hepatitis B and the tetanus and diphtheria toxins.
[0003] Active immunotherapy concepts are now being applied to develop therapeutic cancer vaccines with the intention of treating existing tumors or preventing tumor recurrence as well as for treatment and prevention of chronic viral infection. Many of these techniques have proven to successfully develop increased frequencies of immune cells in circulation that have the ability to specifically kill tumors or pathogen infected cells. However, despite the ability to generate immune cells reactive against tumor antigens, tumor escape mechanisms can overpower this immune response resulting in eventual tumor progression.
[0004] Active immunotherapy of cancer has been shown to be very effective in numerous rodent models. However, the clinically disappointing results of decades of immunotherapy trials of various types in humans have shown the immune system in humans does not perceive the threat/danger of human cancer cells as well as the immune system of rodent models of the same diseases.
[0005] The same is true of chronic viral infection. The innate immune response is able to slow down viral replication and activate cytokines which trigger the synthesis of antiviral proteins. The adaptive immune system neutralizes virus particles and destroys infected cells. However, viruses have developed a number of countermeasures to avoid immune attack and stay moving targets for the immune system.
[0006] There is a need to provide an active immunotherapy that is capable of overcoming tumor and viral immunoavoidance mechanisms and to train the human immune system to perceive the threat/danger of human cancer cells and viral infected cells resulting in an immune response which can eradicate tumors or pathogen-infected cells wherever they might be located in the body.
SUMMARY
SUMMARY
[0007] The present disclosure relates to methods and compositions for inducing a systemic, adaptive immune response against a tumor or pathogen. The method uses a combination of an allogeneic cell therapy and a method for subjecting the tumor or pathogen infected tissue to cellular distress, resulting in the liberation of tumor specific antigen(s) or pathogen specific antigen(s).
[0008] In one aspect, the present disclosure is a method for inducing an adaptive immune response against a tumor or a pathogen in a subject. The method includes the steps of: (1) administering to a subject with cancer or an infectious disease an aliquot of allogeneic cells that are designed to be rejected by the subject immune system in a manner that induces anti-allogeneic Thl immunity;
(2) in the same subject, after allowing time for an anti-allogeneic Thl immune memory to form (about 7 to 14 days), performing an in situ ablation of an accessible tumor lesion or pathogen-infected tissue with an ablation method which causes at least a portion of the tumor or infected tissue to die, preferably by necrosis, (e.g., by methods such as but not limited to electroporation, cryoablation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof); then; (3) injecting a second aliquot of the same allogeneic cells intralesionally (same cells as used to prime), preferably 2-24hrs after the ablation step, creating an immune response that serves as an adjuvant to the uptake of antigen(s) and the subsequent maturation of host antigen presenting cells (i.e., dendritic cells) responding to the necrotic or apoptotic tissue.
Mature antigen presenting cells from the lesion then migrate to the lymph nodes and stimulate systemic anti-tumor or anti-pathogen immunity. In another aspect, the priming step is omitted. The tissue from the tumor or the pathogen infected tissue is ablated in situ and an aliquot of the allogeneic cells are injected after the ablation to create the desired immune response.
(2) in the same subject, after allowing time for an anti-allogeneic Thl immune memory to form (about 7 to 14 days), performing an in situ ablation of an accessible tumor lesion or pathogen-infected tissue with an ablation method which causes at least a portion of the tumor or infected tissue to die, preferably by necrosis, (e.g., by methods such as but not limited to electroporation, cryoablation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof); then; (3) injecting a second aliquot of the same allogeneic cells intralesionally (same cells as used to prime), preferably 2-24hrs after the ablation step, creating an immune response that serves as an adjuvant to the uptake of antigen(s) and the subsequent maturation of host antigen presenting cells (i.e., dendritic cells) responding to the necrotic or apoptotic tissue.
Mature antigen presenting cells from the lesion then migrate to the lymph nodes and stimulate systemic anti-tumor or anti-pathogen immunity. In another aspect, the priming step is omitted. The tissue from the tumor or the pathogen infected tissue is ablated in situ and an aliquot of the allogeneic cells are injected after the ablation to create the desired immune response.
[0009] In another aspect, the present disclosure includes a vaccine for a patient against a tumor or a pathogen. The vaccine includes an antigenic composition comprising antigenic material from the tumor or pathogen and an aliquot of allogeneic cells wherein administration of the antigenic composition to the patient creates a rejection response and stimulates a delayed-type hypersensitivity response to the antigens thereby acting as an adjuvant to the stimulation of systemic anti-tumor or anti-pathogen immunity in the patient.
The vaccine can also include a priming composition wherein the priming composition includes an aliquot of allogeneic cells.
The vaccine can also include a priming composition wherein the priming composition includes an aliquot of allogeneic cells.
[0010] In yet another aspect, the present disclosure includes a method of vaccinating a patient. The method includes the steps of: (1) administering to the subject with cancer or an infectious disease a priming composition that includes an aliquot of allogeneic cells that are designed to be rejected by the subject immune system in a manner that induces anti-allogeneic Thl immunity; (2) in the same subject, after allowing time for an anti-allogeneic Thl immune memory to develop (about 7 to 14 days), injecting, preferably intradermally, an antigenic composition containing a source of tumor antigen or pathogen antigens (e.g., attenuated virus, tumor lysates, heat shock proteins), preferably containing from the same individual autologous lysates of the infected or cancerous tissue, the lysates preferably containing chaperone proteins, and such lysates formulated with an aliquot of allogeneic cells (same cells used to prime the patient) to create a rejection response and stimulate a delayed-type hypersensitivity response to the alloantigens which serve to adjuvant the stimulation of systemic anti-tumor or anti-pathogen immunity. In a further aspect, this method may be practiced without the priming step.
[0011] In another aspect, the present disclosure includes a therapeutic composition for treating a tumor or a pathogen in a patient comprising tumor antigens or pathogen antigens generated in situ and allogeneic cells, wherein the allogeneic cells and the in situ generated antigens elicit an immune response whereby subsequent maturation of the patient's antigen presenting cells systemically stimulate anti-tumor or anti pathogen immunity. The tumor antigens or pathogen antigens are generated in situ from necrosis of the tumor or the pathogen infected tissue. The therapeutic composition may also include a priming composition containing allogeneic cells. The allogeneic cells in the priming composition and in the antigenic composition may include between about 1 x 108 and about 1 x 1010 cells.
[0012] In yet a further aspect, the present description includes a vaccine composition for treating a tumor or a pathogen in a patient comprising antigens generated in situ that include tumor antigens or pathogen antigens and allogeneic cells wherein injecting the patient with the allogeneic cells in the presence of in situ generated antigens creates an immune response whereby subsequent maturation of the patient's antigen presenting cells systemically stimulate anti-tumor or anti pathogen immunity. The tumor antigens in the composition are derived from in situ necrosis of the tumor. The pathogen antigens in the composition are derived from in situ necrosis of the pathogen infected tissue. The composition may also include a priming composition containing allogeneic cells. The allogeneic cells in the priming composition and in the vaccine composition may include between about 1 x 108 and about 1 x 1010 cells.
[0013] In a further aspect, the present disclosure includes a method of vaccinating a patient. The method includes the steps of: (1) administering to the subject with cancer or an infectious disease a priming composition that includes an aliquot of allogeneic cells that are designed to be rejected by the subject immune system in a manner that induces anti-allogeneic Thl immunity; (2) in the same subject, after allowing time for an anti-allogeneic Thl immune memory to develop (about 7 to 14 days), ablating the tumor or pathogen infected tissue in situ to release tumor antigens or pathogen antigens (3) administering a composition of allogeneic cells (same cells used to prime the patient) to create a rejection response and stimulate a delayed-type hypersensitivity response to the alloantigens which serve to adjuvant the stimulation of systemic anti-tumor or anti-pathogen immunity. In a further aspect, this method may be practiced without the priming step.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0014] The present disclosure includes a method for stimulating anti-tumor or anti-pathogen immunity in patients. The method involves first "priming" of the patient to develop Thl anti-alloantigen immune memory by infusion of an aliquot of allogeneic cells. It is desired that the infusion of allogeneic cells stimulates the patient's immune system to react against the allogeneic cells.
A
time period is allowed to elapse until the patient's immune system is allowed to form an anti-allogeneic memory. In some embodiments, a patient may need a booster of allogeneic cells to develop the appropriate Thl immune memory.
A
time period is allowed to elapse until the patient's immune system is allowed to form an anti-allogeneic memory. In some embodiments, a patient may need a booster of allogeneic cells to develop the appropriate Thl immune memory.
[0015] Patient as used herein includes not only mice but also humans. Thl response as used herein refers to production of a cytokine profile that activates T-cells and macrophages. Thl response is to be distinguished from Th2 response which activates mainly an immune response that depends upon antibodies and is antagonistic to the Thl response.
[0016] The next step includes injury and/or death of cells within a tumor bed or pathogen-infected tissue after the patient develops sufficient anti-allogeneic Thl immune memory. Tissue injury or death releases cellular components and recruits scavenger cells to the injury site. The release of cellular components during tissue injury or tissue death by necrosis is critical for the in situ generation of tumor or pathogen antigens. A variety of methods are known in the art to cause tissue injury or death within a tumor bed or pathogen infected tissue. Preferably death is by necrosis, which causes recruitment of scavenger cells to the injury site. In some preferred embodiments, tissue death or injury is by cryoablation or by irreversible electroporation. Alternatively, tissue is ablated ex-vivo and the released components injected into the patient.
[0017] The scavenger cells, including immature dendritic cells can pick up antigens released from the damaged or dead tissues. A second aliquot of allogeneic cells are injected intralesionally in order to cause the maturation of dendritic cells (DC) for the priming of Thl immunity to the antigens. By intralesionally is meant administration of the composition of this invention through injection or otherwise directly into a cancerous area or tumor or a pathogen infected tissue. In preferred embodiments, all of the allogeneic cells administered to the patient are from the same source. Preferably, the allogeneic cells are administered between about 2 and about 24 hours after ablation of the tissue. This method is especially useful in the treatment of solid or metastatic tumors, particularly in patients with tumor lesions resident in the prostate, breast, bone, liver, lung, or kidney.
[0018] It is desirable for the patient to develop a strong delayed-type hypersensitivity (DTH) reaction upon introduction of the second aliquot of allogeneic cells resulting in rejection of the allogeneic cells due to the fact that the patient has been primed to Thl immunity against the allogeneic cells introduced by the first aliquot. The by-stander effect of the anti-alloantigen DTH reaction can produce "danger signals" which serve to cause the DC, collecting and processing antigens from the damaged tissue, to mature and migrate to the draining lymph nodes. The combination of the induction of tissue injury and the DTH rejection response can create an inflammatory environment which leads to Thl immunity against the antigens released from the damaged tissue.
[0019] The general state of inflammation caused by the treatment process can serve to cause the DC to program T-cells to Thl immunity against antigens in the damaged tissue resulting in a systemic adaptive immune response to the tumor or pathogen-infected cells and the disabling of tumor and pathogen-mediated immune avoidance mechanisms. By adaptive immunity is meant that the patient's defenses are mediated by B and T cells following exposure to antigen and that such defenses exhibit specificity, diversity, memory, and self/nonself recognition. Such adaptive immunity is systemic within the patient.
Adaptive immunity is to be distinguished from innate immunity which is non-specific and exists prior to exposure to the antigen.
Adaptive immunity is to be distinguished from innate immunity which is non-specific and exists prior to exposure to the antigen.
[0020] In some embodiments, ablation followed by administration of the allogeneic cells may be sufficient to generate the desired response. In other words, the priming of the patient by a first aliquot of allogeneic cells may be omitted. In these embodiments, tissue from the tumor or infected by a pathogen is ablated followed by injection of an aliquot of allogeneic cells.
[0021] The present invention also includes a method of vaccinating a patient having cancerous cells or an infected tissue. This method can be used to vaccinate a patient using in situ generated antigens from the cancerous cells or infected tissue in conjunction with administration of allogeneic cells. This method can also be used for patients with hematological malignancies (e.g., Chronic Lymphocytic Leukemia, Multiple Myeloma, and non-Hodgkin's lymphomas) or viral infectious diseases (e.g., hepatitis B or C, herpes, HIV) and other disorders where the affected lesions are not easily assessable for ablation.
[0022] The method involves first "priming" of the patient to develop Thl anti-alloantigen immune memory by infusion of a first aliquot of allogeneic cells.
It is desired that the infusion of allogeneic cells stimulates the patient's immune system to react against the allogeneic cells. A time period is allowed to elapse until the patient's immune system is allowed to form an anti-allogeneic memory.
In some embodiments, a patient may need a booster of allogeneic cells to develop the appropriate Thl immune memory.
It is desired that the infusion of allogeneic cells stimulates the patient's immune system to react against the allogeneic cells. A time period is allowed to elapse until the patient's immune system is allowed to form an anti-allogeneic memory.
In some embodiments, a patient may need a booster of allogeneic cells to develop the appropriate Thl immune memory.
[0023] The next step includes exposing the patient's immune system to antigens from the cancerous cells or the pathogen infected tissue in addition to the activated allogeneic cells described herein. In preferred embodiments, the antigens are generated in situ by ablation of the cancerous cells/tumors or the pathogen infected tissue. In situ ablation of the tumors or the pathogen infected tissue results in the release of tumor antigens or pathogen antigens in the patient.
The subsequent administration of the allogeneic cells at site of the lesion results in the desired immune response by creating a rejection response in the patient and stimulating a delayed-type hypersensitivity response to the antigens. The ablation can be by cryoablation, electroporation or other means that result in necrotic death of tumors or pathogen infected tissue
The subsequent administration of the allogeneic cells at site of the lesion results in the desired immune response by creating a rejection response in the patient and stimulating a delayed-type hypersensitivity response to the antigens. The ablation can be by cryoablation, electroporation or other means that result in necrotic death of tumors or pathogen infected tissue
[0024] In other embodiments, after the priming step, the method can include administering into the patient an antigenic composition that includes an autologous lysate containing antigens from the cancerous cells or the infected tissue. This composition also includes an aliquot of the allogeneic cells, i.e.
allogeneic cells that are from the same source as the allogeneic cells used in the priming step. The injection of the antigenic composition can create a rejection response in the patient and can stimulate a delayed-type hypersensitivity response to the antigens.
allogeneic cells that are from the same source as the allogeneic cells used in the priming step. The injection of the antigenic composition can create a rejection response in the patient and can stimulate a delayed-type hypersensitivity response to the antigens.
[0025] The scavenger cells, including immature dendritic cells can pick up the antigens resulting from the in situ ablation or from the autologous lysate.
The allogeneic cells can cause the maturation of dendritic cells for the priming of Thl immunity to the antigens. It is desirable for the patient to develop a strong DTH reaction upon introduction of the allogeneic cells at the site of the necrotic lesion due to the fact that the patient has been primed to Thl immunity against the allogeneic cells introduced by the first aliquot of allogeneic cells during the priming step.
The allogeneic cells can cause the maturation of dendritic cells for the priming of Thl immunity to the antigens. It is desirable for the patient to develop a strong DTH reaction upon introduction of the allogeneic cells at the site of the necrotic lesion due to the fact that the patient has been primed to Thl immunity against the allogeneic cells introduced by the first aliquot of allogeneic cells during the priming step.
[0026] The general state of inflammation caused by the treatment process can serve to cause the DC to program T-cells to Thl immunity against the antigens at the ablation site resulting in a systemic adaptive immune response to the tumor or pathogen-infected cells and the disabling of tumor and pathogen-mediated immune avoidance mechanisms.
[0027] The present disclosure also provides a method for enhancing the immunogenicity of weakly immunogenic or non-immunogenic tumors and a method to deviate an immune response from a non-protective immune response (e.g., Th2 response) to a protective immune response (e.g., Th1). Such diseases include, for example, all types of cancers and diseases caused by infections with a variety of pathogens (e.g., Hepatitis viruses, fungal infections such as aspergillus, HIV, malaria, typhoid, cholera, herpes viruses, Chlamydia, and HPV).
[0028] The present disclosure also includes a therapeutic composition for treating a tumor or a pathogen in a patient. The therapeutic composition preferably includes allogeneic cells and antigens, generated in situ, comprising the products of tumor necrosis or pathogen infected tissue necrosis. The therapeutic composition may also include a priming composition. The priming composition generally contains allogeneic cells that are injected into the patient to generate a rejection response by the patient's immune system in a manner that induces an allogeneic Thl immunity.
[0029] The therapeutic composition includes antigenic material from the tumor or pathogen-infected tissue and an aliquot of allogeneic cells. In preferred embodiments, the antigenic material is in situ released antigenic material containing antigens from the cancerous cells or from infected tissue. The antigenic material can be derived in situ from tissue necrosis of the tumor or the pathogen-infected tissue. Preferably, the antigenic material is derived from ablation of the tumor or pathogen-infected tissue.
[0030] The ablation may be done in vivo, in situ or ex vivo. In some embodiments, the antigenic material includes heat shock proteins released upon ablation of the tissue from a tumor or pathogen-infected tissue.
[0031] The therapeutic composition also includes allogeneic cells. In embodiments with in situ generated antigenic material, the therapeutic composition includes allogeneic cells that are administered directly into the lesion site containing the in situ generated antigens. The allogeneic cells, when injected into the patient, can create a rejection response and stimulate a delayed-type hypersensitivity response to the antigens thereby acting as an adjuvant to the stimulation of systemic anti-tumor or anti-pathogen immunity in the patient.
[0032] The therapeutic compositions may include other components that act as adjuvants to the response generated by the priming composition and the allogeneic cells. The priming composition and allogeneic cells may include other components generally found in therapeutic composition, for example, preservatives. The addition of these components are within the scope of this invention.
[0033] In some embodiments, the therapeutic composition may only include the allogeneic cells and in situ generated antigens and not the priming composition.
The priming composition may not be needed to obtain the desired immune response.
The priming composition may not be needed to obtain the desired immune response.
[0034] The present invention also includes a vaccine composition for a patient against a tumor or a pathogen. The vaccine preferably includes a priming composition and an antigenic composition. The priming composition generally contains allogeneic cells which are injected into the patient to generate a rejection response by the patient's immune system in a manner that induces an allogeneic Thl immunity.
[0035] The antigenic composition includes antigenic material from the tumor or pathogen-infected tissue and an aliquot of allogeneic cells. In some embodiments, the antigenic material is an autologous lysate containing antigens from the cancerous cells or from infected tissue. The antigenic material can be derived from tissue necrosis of the tumor or the pathogen-infected tissue.
Preferably, the antigenic material is derived from ablation of the tumor or pathogen-infected tissue. The ablation may be done in vivo or ex vivo. In some embodiments, the antigenic material includes heat shock proteins released upon ablation of the tissue from a tumor or pathogen-infected tissue. The antigenic composition also includes allogeneic cells. The antigenic material and the allogeneic cells may be combined together or packaged separately.
Preferably, the antigenic material is derived from ablation of the tumor or pathogen-infected tissue. The ablation may be done in vivo or ex vivo. In some embodiments, the antigenic material includes heat shock proteins released upon ablation of the tissue from a tumor or pathogen-infected tissue. The antigenic composition also includes allogeneic cells. The antigenic material and the allogeneic cells may be combined together or packaged separately.
[0036] The present disclosure also includes an in situ generated vaccine composition. The antigenic material in this vaccine is generated in situ and the allogeneic cells are administered to the patient as an adjuvant, preferably intralesionally. The in situ generation of antigenic material can be accomplished by ablation of the tumor or pathogen infected tissue within the patient releasing the antigenic material. The ablation can be by cryoablation, electroporation or other means that result in necrotic death of tumors or pathogen infected tissue.
[0037] In embodiments with in situ generated antigens, the antigenic composition administered to the patient includes allogeneic cells and these cells are administered at the necrotic lesion site containing the released antigens.
The antigenic composition, when injected into the patient, can create a rejection response and stimulate a delayed-type hypersensitivity response to the antigens thereby acting as an adjuvant to the stimulation of systemic anti-tumor or anti-pathogen immunity in the patient.
The antigenic composition, when injected into the patient, can create a rejection response and stimulate a delayed-type hypersensitivity response to the antigens thereby acting as an adjuvant to the stimulation of systemic anti-tumor or anti-pathogen immunity in the patient.
[0038] The vaccine may include other components that act as adjuvants to the response generated by the priming composition and the antigenic composition.
The priming composition and antigenic composition may include other components generally found in vaccines, for example, preservatives. The addition of these components are all within the scope of this invention.
The priming composition and antigenic composition may include other components generally found in vaccines, for example, preservatives. The addition of these components are all within the scope of this invention.
[0039] In some embodiments, the vaccine may only include the antigenic composition and not the priming composition. The antigenic composition may be sufficient to obtain the desired immune response.
[0040] The therapeutic vaccines of the present invention are useful for the prevention and treatment of diseases such as cancer or chronic viral diseases that develop and/or persist by suppressing or escaping the immune response.
Priming Step
Priming Step
[0041] The purpose of the priming step is to create anti-allogeneic Thl immunity in a patient that can be recalled upon subsequent exposure to the alloantigens. Priming occurs by exposing a patient to an aliquot of allogeneic cells and the subsequent rejection of these allogeneic cells when a second aliquot is administered to the patient by the patient's immune system resulting from immune memory. Preferably, the patients are not immunosuppressed prior to priming, as this will inhibit the ability of the patient to reject the infused allogeneic cells and will also inhibit the development of anti-alloantigen Thl immunity.
[0042] In one embodiment of the present invention, the patient's immune system is skewed to generate Thl immunity. It is preferable to manipulate the allogeneic cells such that Thl and not Th2 immunity develops in response to the rejection of the allogeneic cells. In one embodiment, the patient's immune system can be skewed to produce Th-1 response by administering allogeneic cells that are producing Thl cytokines (e.g., IFN-gamma and TNF-alpha) when infused. Thl cytokines can assist in skewing the immune response to the alloantigens to Thl type immunity. Other methods of skewing a patient's immune system to produce Th-1 immunity are also within the scope of this invention.
[0043] The allogeneic cells used to first prime the patients and then later used for either intralesional administration (after induction of cell death) or as an adjuvant to a source of pathogenic or tumor material, are preferably allogeneic activated T-cells, more preferably allogeneic activated CD4+ Thl cells, more preferably allogeneic CD4+ T-cells that have differentiated into effector or memory cells and produce high levels of Type 1 cytokines, such as IL-2, IL-15, IFN-gamma, TNF-alpha and also express, preferably at high density, effector molecules such as CD40L, TRAIL and FasL on the cell surface but do not produce IL-4 or other Type 2 cytokines. CD40 ligation of innate immune cells (e.g., dendritic cells, macrophages and NK cells) has the capacity to induce high levels of the cytokine IL-12, which polarizes CD4+ T cells toward the Th 1 type immunity, enhances proliferation of CD8+ T cells, and activates NK cells.
These pro-inflammatory events can enable the consistent development of Thl immunity to the alloantigens on the allogeneic cells upon rejection by the patient's immune system.
These pro-inflammatory events can enable the consistent development of Thl immunity to the alloantigens on the allogeneic cells upon rejection by the patient's immune system.
[0044] In the priming step, the activated allogeneic T-cells are administered to the patient, preferably intravenously, but can also be administered intradermally.
The allogeneic cells are preferably derived from a deliberately HLA-mismatched donor. Preferred dosage in an aliquot of allogeneic cells for intravenous infusion is at least about 1 x 107 cells and more preferred is between about 1 x 108 to 1 x 1010 cells. Dosages of allogeneic cells outside this range that can primarily generate an immune response are also within the scope of this invention.
The allogeneic cells are preferably derived from a deliberately HLA-mismatched donor. Preferred dosage in an aliquot of allogeneic cells for intravenous infusion is at least about 1 x 107 cells and more preferred is between about 1 x 108 to 1 x 1010 cells. Dosages of allogeneic cells outside this range that can primarily generate an immune response are also within the scope of this invention.
[0045] It is desirable to test the patients for development of Thl anti-alloantigen immunity prior to the ablation of affected tissue or administration of the antigenic composition. The development of Thl anti-alloantigen immunity may take at least about 7 days. Preferably, the patient is allowed between about 7 days to about 14 days to develop Thl anti-alloantigen immunity. The development of Thi anti-alloantigen immunity can be measured by, for example, ELISPOT assay. Other methods of testing patients for development of Thl anti-alloantigen immunity are also within the scope of this invention. If the Thl anti-alloantigen immunity is weak, additional booster injections of allogeneic cells can be administered. Booster injections are preferably made intradermally to generate a delayed type hypersensitivity (DTH) reaction in the skin.
Generation of Allogeneic T-cells
Generation of Allogeneic T-cells
[0046] It is desirable that allogeneic T-cells can be generated such that, upon, activation and infusion into a patient, a Th-1 immunity can be generated by the patient. A preferred method for producing allogeneic cells with the properties necessary for stimulation of anti-allogeneic Thl immunity involves: (1) the collection of mononuclear cell source material by leukapheresis from normal screened donors; (2) the isolation of CD4 T-cells from the source material;
(3) the activation of the CD4+ cells with immobilized anti-CD3 and anti-CD28 monoclonal antibodies (mAbs) on days 0, 3 and 6; (4) the activation of the cells again on day 9 with immobilized anti-CD3 and anti-CD28 mAbs and the infusion of the cells within 24h of activation.
Cell Death Step
(3) the activation of the CD4+ cells with immobilized anti-CD3 and anti-CD28 monoclonal antibodies (mAbs) on days 0, 3 and 6; (4) the activation of the cells again on day 9 with immobilized anti-CD3 and anti-CD28 mAbs and the infusion of the cells within 24h of activation.
Cell Death Step
[0047] In situ cell death or cell injury can result in recruitment of DC to the lesion and provide a source of antigen for uptake by DC. It is preferable that target tissues be destroyed by a process which causes death by necrosis. By necrosis it is meant the death of individual cells or groups of cells such that amounts of intracellular components are released to the environment. For purposes of this application, necrosis includes a cell death by a variety of methods including cryoablation, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radio frequency energy or a combination thereof.
Necrotically killed cells activate endogenous signals of distress responsible for the recruitment and maturation of DC, stimuli that would not be generated by healthy or apoptotically dying cells. Further, exposure of immature DC to these stimuli provides maturation signals, critical for the initiation of local and systemic Thl immunity.
Necrotically killed cells activate endogenous signals of distress responsible for the recruitment and maturation of DC, stimuli that would not be generated by healthy or apoptotically dying cells. Further, exposure of immature DC to these stimuli provides maturation signals, critical for the initiation of local and systemic Thl immunity.
[0048] In one preferred embodiment, in order to cause death by necrosis, it is preferred that the target tissue is frozen in situ. Cryosurgery is a well-aimed and controlled procedure capable of inducing tissular necrosis by the application of liquid N2 or argon gas. The biologic changes that occur during and after cryosurgery have been studied in vitro and in vivo. Tissue injury and necrosis is induced by cell freezing and by the vascular stasis that develops after thawing.
Cryosurgery (in situ freezing) has been known to elicit an antigenic stimulus (comparable to that obtained through the parenteral administration of antigen) capable of generating a specific immunologic response against autologous antigens of the frozen tissue.
Cryosurgery (in situ freezing) has been known to elicit an antigenic stimulus (comparable to that obtained through the parenteral administration of antigen) capable of generating a specific immunologic response against autologous antigens of the frozen tissue.
[0049] Cryoablation can cause peptides to be released from lysed tumor or pathogen-infected cells for antigen processing by DC and creates a pro-inflammatory cytokine environment. Cytokines released after cryoablation such as IL-1, IL-2, TNF-a, IFN-y, and GM-CSF can activate the T, NK, and Langerhans cells essential to an immune response capable of destroying cancer or pathogen infected cells.
[0050] In another preferred embodiment, in order to cause death by necrosis, it is preferred that the target tissue is subject to irreversible electroporation.
Irreversible electroporation is a tissue ablation technique in which micro to milli-second electrical pulses are delivered to the tissue to produce cell necrosis through irreversible cell membrane permeabilization. In irreversible electroporation, the cellular membranes of the cells between the electrodes are disrupted causing cellular necrosis. Irreversible electroporation can cause antigens to be released from lysed tumor or pathogen¨infected cells for antigen processing by DC and creates a pro-inflammatory cytokine environment.
Irreversible electroporation is a tissue ablation technique in which micro to milli-second electrical pulses are delivered to the tissue to produce cell necrosis through irreversible cell membrane permeabilization. In irreversible electroporation, the cellular membranes of the cells between the electrodes are disrupted causing cellular necrosis. Irreversible electroporation can cause antigens to be released from lysed tumor or pathogen¨infected cells for antigen processing by DC and creates a pro-inflammatory cytokine environment.
[0051] Another preferred method for generating a source of antigen is to isolate autologous chaperone proteins, also known as heat shock proteins (HSP), from dead infected tissue or tumors. HSPs are among the major targets of the immune response to bacterial, fungal and parasitic pathogens. Certain chaperones in extracellular milieu may also modulate innate and adaptive immunity due to their ability to chaperone polypeptides and to interact with the host's immune system, particularly professional antigen-presenting cells.
Vaccination with heat shock proteins from tumor have been shown to elicit an anti-tumor response. Current studies indicate that the immunogenicity of HSPs is derived from the antigenic peptides with which they associate.
Vaccination with heat shock proteins from tumor have been shown to elicit an anti-tumor response. Current studies indicate that the immunogenicity of HSPs is derived from the antigenic peptides with which they associate.
[0052] A preferred method for isolation of chaperone proteins for use as an antigen source is described by Katsantis in US Pat No. 6,875,849. Additional methods are described by Srivastava in US Pat Nos. 6,797,480; 6,187,312, 6,162,436; 6,139,841; 6,136,315; and 5,837,251.
Adjuvant Step
Adjuvant Step
[0053] The purpose of the adjuvant step is to cause the maturation of DC to stimulate Thl immunity against antigens taken up in the lesions containing dead target tissue. This can be accomplished by the injection of the same allogeneic cells, i.e. allogeneic cells of the same origin as those used to prime the patient.
This aliquot of the allogeneic cells are, preferably, injected intralesionally, i.e.
directly into the necrotic lesion caused by the cryoablation, or other method of cell death. Alternatively, when chaperone proteins are used as the source of antigen, the same allogeneic cells used to prime the patient are injected with the chaperone proteins, preferably intradermally. The dosage of the allogeneic cells to generate the desired immune response is generally at least about 1 x 107 cells and more preferred is between about 1 x 108 to 1 x 1010 cells. Dosages of allogeneic cells outside this range that can generate the desired immune response are also within the scope of this invention. The preparation of the allogeneic cells is the same as described above.
This aliquot of the allogeneic cells are, preferably, injected intralesionally, i.e.
directly into the necrotic lesion caused by the cryoablation, or other method of cell death. Alternatively, when chaperone proteins are used as the source of antigen, the same allogeneic cells used to prime the patient are injected with the chaperone proteins, preferably intradermally. The dosage of the allogeneic cells to generate the desired immune response is generally at least about 1 x 107 cells and more preferred is between about 1 x 108 to 1 x 1010 cells. Dosages of allogeneic cells outside this range that can generate the desired immune response are also within the scope of this invention. The preparation of the allogeneic cells is the same as described above.
[0054] To initiate an immune response and overcome the natural tolerance the immune system has to self tissues, the antigens released after necrotic cell death or associated with the chaperone proteins must be taken up by DC and presented with immune activating components that signal "danger". The memory immune response against the allogeneic cells create this "danger".
[0055] The tissue resident DC, termed immature DC, are able to capture the in situ generated antigens from the environment, but are deficient in stimulating T
cells. In response to pathogen infection and the ensuing inflammatory response, DC undergo a differentiation process called maturation, whereby they up-regulate the capacity to migrate to draining lymph nodes and present the captured antigens to T cells. To activate Thl CD4+ T cells and CTL, the DC has to integrate a number of maturation/differentiation stimuli. At the site of pathogen or tumor encounter, exposure to pathogen or tumor-derived determinants, proinflammatory cytokines, and/or cell debris induces the first steps in the maturation process. This includes the up-regulation of costimulatory molecules and chemokine receptors, whereby the DC acquire the ability to present antigens to T cells and migrate to the lymph node, respectively. At the lymph node, encounter of cognate CD4+ T cells provides additional differentiation stimuli to the DC, which regulate the survival of the activated T
cells and the polarization of the CD4+ T cells.
cells. In response to pathogen infection and the ensuing inflammatory response, DC undergo a differentiation process called maturation, whereby they up-regulate the capacity to migrate to draining lymph nodes and present the captured antigens to T cells. To activate Thl CD4+ T cells and CTL, the DC has to integrate a number of maturation/differentiation stimuli. At the site of pathogen or tumor encounter, exposure to pathogen or tumor-derived determinants, proinflammatory cytokines, and/or cell debris induces the first steps in the maturation process. This includes the up-regulation of costimulatory molecules and chemokine receptors, whereby the DC acquire the ability to present antigens to T cells and migrate to the lymph node, respectively. At the lymph node, encounter of cognate CD4+ T cells provides additional differentiation stimuli to the DC, which regulate the survival of the activated T
cells and the polarization of the CD4+ T cells.
[0056] The maturation of DC occurs at the site of antigen uptake and the recall rejection response serves as an adjuvant to provide the appropriate inflammatory danger signals necessary for DC maturation, migration to the lymph nodes and the programming for Thl immunity against the antigens uptaken in the lesion.
Examples Animals
Examples Animals
[0057] Balb/c mice were hosts and C57B1/6 (B6) mice were used as source of Thl cells. All mice were 6 to 10 weeks old, were maintained in a specific pathogen-free facility at the Hadassah-Hebrew University Medical Center, and were treated on an approved animal protocol.
Preparation of Allogeneic Thl Memory Cells
Preparation of Allogeneic Thl Memory Cells
[0058] Spleen cells from male C57BL/6 mice were harvested and treated with ammonium chloride-potassium (ACK) buffer for lysis of red blood cells.
Approximately 70-100 million cells were isolated per spleen. CD4+ T-cells were then purified by positive selection (purity >98%) using CD4 immunomagnetic particles on an MS column (Miltenyi Biotec, Germany), approximately 8-12 million CD4 cells were isolated with a yield of 50-60%.
Thl memory cells were generated by expansion with anti-CD3 and anti-CD28¨
coated paramagnetic beads (CD3/CD28 T-cell expander beads, Dynal/Invitrogen) at an initial bead:CD4 cell ratio of 3:1. The purified CD4 cells were incubated with 20 IU/mL recombinant mouse (rm)IL-2, 20 ng/mL
rmIL-7, and 10 ng/mL rmIL-12 (Peprotech, New Jersey) and 10 lug/mL
antimurine IL-4 mAb (Becton Dickenson) in RPMI 1640 media containing 10%
FBS, penicillin-streptomycin-glutamine, nonessential amino acids (NEAA) (Biological Industries, Israel) and 3.3 mM N-acetyl-cysteine (NAC; Sigma) (complete media). Additional cytokine-containing complete media with rmIL-2 and rmIL-7 was added to the CD4 cultures daily from days 3 to 6 to maintain the cell concentration between 0.5 and 1 x 106 cells/mL. Additional CD3/CD28 beads were added daily from day 3 to day 6. The number of beads added was calculated to maintain a 1:1 bead:cell ratio as the cells expanded. After 6 days in culture, the CD4 cells expanded approximately 80 to100-fold and were harvested and debeaded by physical disruption and passage over a magnet. The phenotype of the harvested cells used in experiments were >95% CD4+, CD45R0+, CD62L10, IFN-a+ and IL-4-.
CD3/CD28 Nanobead Preparation
Approximately 70-100 million cells were isolated per spleen. CD4+ T-cells were then purified by positive selection (purity >98%) using CD4 immunomagnetic particles on an MS column (Miltenyi Biotec, Germany), approximately 8-12 million CD4 cells were isolated with a yield of 50-60%.
Thl memory cells were generated by expansion with anti-CD3 and anti-CD28¨
coated paramagnetic beads (CD3/CD28 T-cell expander beads, Dynal/Invitrogen) at an initial bead:CD4 cell ratio of 3:1. The purified CD4 cells were incubated with 20 IU/mL recombinant mouse (rm)IL-2, 20 ng/mL
rmIL-7, and 10 ng/mL rmIL-12 (Peprotech, New Jersey) and 10 lug/mL
antimurine IL-4 mAb (Becton Dickenson) in RPMI 1640 media containing 10%
FBS, penicillin-streptomycin-glutamine, nonessential amino acids (NEAA) (Biological Industries, Israel) and 3.3 mM N-acetyl-cysteine (NAC; Sigma) (complete media). Additional cytokine-containing complete media with rmIL-2 and rmIL-7 was added to the CD4 cultures daily from days 3 to 6 to maintain the cell concentration between 0.5 and 1 x 106 cells/mL. Additional CD3/CD28 beads were added daily from day 3 to day 6. The number of beads added was calculated to maintain a 1:1 bead:cell ratio as the cells expanded. After 6 days in culture, the CD4 cells expanded approximately 80 to100-fold and were harvested and debeaded by physical disruption and passage over a magnet. The phenotype of the harvested cells used in experiments were >95% CD4+, CD45R0+, CD62L10, IFN-a+ and IL-4-.
CD3/CD28 Nanobead Preparation
[0059] Biotinylated mouse anti-CD3 and anti-CD28 mAbs (BD Pharmingen) were each diluted in 4001,t1 of PBS to a final concentration of 251Ag/m1 and then mixed in a 1:1 ratio so that the final volume was 8001,t1. 201,t1 of Strepavidin-coated nanobeads (Miltenyi, Germany) were washed and diluted to a final volume of 2001,t1 in PBS. The 8001,t1 of the CD3/CD28 mAb solution and the 2001,t1 of diluted nanobeads were then mixed so that the final concentration of each mAb was 10pg/m1 in a total volume of lml. The mixture was placed on a rotating mixing device for 30 min at RT. The mAb conjugated nanobeads were then passed over an MS column (Miltenyi, Germany) on a magnet and washed thoroughly. The retained nanobeads were then released from the column and resuspended in 2001,t1 of PBS. The nanobeads were not able to activate naïve T-cells. Therefore, the nanobeads were tittered against harvested Thl memory cells that had been previously activated 6 days prior with CD3/CD28 T-cell expander beads (Dynal, Norway). While there were slight variations per batch, generally 201,t1/107cells was found to provide optimal activation of previously activated Thl memory cells.
CD3/CD28 cross-linking
CD3/CD28 cross-linking
[0060] In experiments that required the infusion of activated Thl memory cells, the harvested Thl cells were incubated with a pre-tittered concentration of CD3/CD28-conjugated nanobeads prior to infusion. For optimal activation, the cells had to be incubated with the nanobeads for a minimum of 4h and a maximum of 18h. Optimal activation caused production of IFN-a and upregulation of CD4OL and FasL on the cell surface. For these experiments, all infusions of CD3/CD28 cross-linked Thl memory cells occurred after 4-8h of pre-incubation. Cells were thoroughly washed prior to infusion to remove any unassociated nanobeads. Cross-linked Thl memory cells used in these experiments expressed FasL and CD4OL on the cell surface and produced in excess of 2000ng/m1/106 cells/6h IFN-a and less than 20pg/m1 IL-4 per 106 cells/6h. Thl memory cells without CD3/CD28 cross-linking did not produce cytokines or express FasL or CD4OL.
Cryotherapy
Cryotherapy
[0061] Cryotherapy was performed with a spherical nitrous oxide cryoprobe, 3 mm in diameter. The gas was maintained at a pressure of 50 bars and the Joule-Thomson effect allowed to attain temperatures ranging from ¨30 to ¨40 C in the tissue. An incision was made in the centre of the tumor, the cryoprobe was placed in contact with the tumor (it was inserted 1-2 mm deep):
the aim was to influence it by freezing but not to destroy it completely.
Three cycles of rapid freezing (lasting for 20 s) followed by slow thawing were applied. The ice ball was produced at the center of the lesion and reached about two thirds of the total tumor volume.
Example #1:
the aim was to influence it by freezing but not to destroy it completely.
Three cycles of rapid freezing (lasting for 20 s) followed by slow thawing were applied. The ice ball was produced at the center of the lesion and reached about two thirds of the total tumor volume.
Example #1:
[0062] To test the ability of allogeneic Thl cells to stimulate systemic anti-tumor immunity in extensive metastatic disease, the following protocol was tested. Lethal doses of tumor cells including BCL1 leukemia, 4T1 breast cancer and 3LL lung cancer were infused intravenously into mice on day 0 and the tumor cells were also injected intradermally to establish a solid tumor mass.
On day 7, the mice were given a 1 x 105 dose of allogeneic Thl cells. On day 14, the mice were treated intratumorally by injection of either: (a) saline; (b) saline+partial cryoablation of tumor; (c) allogeneic Thl cells at a dose of cells; or (d) allogeneic Thl cells+partial cryoablation of tumor. The results of surviving animals at 90 days is shown below (n=10):
Intratumoral BCL1 4T1 3LL
treatment Leukemia Breast Lung Saline 0 (0%) 0 (0%) 0 (0%) S aline+cryo ablation 0 (0%) 0 (0%) 0 (0%) Thl alone 1( 10%) 1(10%) 2 (20%) Thl+cryo ablation 4 (40%) 5 (50%) 8 (80%) Example #2
On day 7, the mice were given a 1 x 105 dose of allogeneic Thl cells. On day 14, the mice were treated intratumorally by injection of either: (a) saline; (b) saline+partial cryoablation of tumor; (c) allogeneic Thl cells at a dose of cells; or (d) allogeneic Thl cells+partial cryoablation of tumor. The results of surviving animals at 90 days is shown below (n=10):
Intratumoral BCL1 4T1 3LL
treatment Leukemia Breast Lung Saline 0 (0%) 0 (0%) 0 (0%) S aline+cryo ablation 0 (0%) 0 (0%) 0 (0%) Thl alone 1( 10%) 1(10%) 2 (20%) Thl+cryo ablation 4 (40%) 5 (50%) 8 (80%) Example #2
[0063] In order to investigate whether treatment of patients with solid tumors might benefit from the present invention, the experiment design above was repeated in animals that only received intradermal injections of tumors creating solid tumor masses. The results were similar to those obtained with animals with metastatic disease.
Intratumoral BCL1 4T1 3LL
treatment Leukemia Breast Lung Saline 0 (0%) 0 (0%) 2 (20%) Thl alone 0 (0%) 0 (0%) 1 (10%) s aline+cryo ablation 0 (0%) 0 (0%) 2 (20%) Thl+cryo ablation 6 (60%) 7 (70%) 9 (90%)
Intratumoral BCL1 4T1 3LL
treatment Leukemia Breast Lung Saline 0 (0%) 0 (0%) 2 (20%) Thl alone 0 (0%) 0 (0%) 1 (10%) s aline+cryo ablation 0 (0%) 0 (0%) 2 (20%) Thl+cryo ablation 6 (60%) 7 (70%) 9 (90%)
[0064] The combination of Thl cells with cryotherapy results in high cure rates.
Cryotherapy kills tumors by necrosis, which is thought to be a more pathological type of cell death than death by apoptosis (the type of death caused by chemotherapy). It is thought that the cryotherapy makes the tumors more immunogenic and therefore the combination of allogeneic Thl cells with necrotic tumor death creates a type of tumor vaccine leading to systemic anti-tumor immunity.
Cryotherapy kills tumors by necrosis, which is thought to be a more pathological type of cell death than death by apoptosis (the type of death caused by chemotherapy). It is thought that the cryotherapy makes the tumors more immunogenic and therefore the combination of allogeneic Thl cells with necrotic tumor death creates a type of tumor vaccine leading to systemic anti-tumor immunity.
[0065] Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.
Claims (19)
1. A therapeutic composition for treating a tumor or pathogen in a patient comprising:
allogeneic cells; and antigens comprising the product of tumor necrosis or pathogen infected tissue necrosis, wherein the antigens are generated in situ, whereby the allogeneic cells and the in situ generated antigens elicit an immune response by the patient to create an anti-tumor or anti-pathogen immunity.
allogeneic cells; and antigens comprising the product of tumor necrosis or pathogen infected tissue necrosis, wherein the antigens are generated in situ, whereby the allogeneic cells and the in situ generated antigens elicit an immune response by the patient to create an anti-tumor or anti-pathogen immunity.
2. A vaccine composition comprising:
an adjuvant comprising allogeneic cells; and antigens generated in situ by necrosis of diseased cells or tissue, wherein the presence of the adjuvant at the necrotic site along with the in situ generated antigens elicit an immune response by the patient to create immunity against the disease.
an adjuvant comprising allogeneic cells; and antigens generated in situ by necrosis of diseased cells or tissue, wherein the presence of the adjuvant at the necrotic site along with the in situ generated antigens elicit an immune response by the patient to create immunity against the disease.
3. The composition of claims 1 and 2 further comprising a priming composition wherein the priming composition comprises allogeneic cells.
4. The composition of claims 1 and 2 wherein the antigens are generated in situ by ablation of the tumor or pathogen infected tissue.
5. The composition of claim 4 wherein the ablation is by cryoablation.
6. The composition of claim 4 wherein the ablation is by electroporation.
7. The composition of claims 1 and 2 wherein the antigens comprise tumor or pathogen antigens, heat shock proteins and combinations thereof.
8. The composition of claims 1 and 2 wherein the allogeneic cells are activated T-cells.
9. The composition of claims 1 and 2 wherein the allogeneic cells express high levels of Type 1 cytokines.
10. The composition of claims 1 and 2 wherein the allogeneic cells express a high density of CD40L, TRAIL, FasL and combinations thereof on the cell surface.
11. A method of inducing an adaptive immune response against a tumor or a pathogen in a patient, the method comprising:
generating antigens from the disease or pathogen infection in situ; and administering allogeneic cells directed to the site of the in situ generated antigens thereby creating an immune response that serves as an adjuvant to the uptake of antigens from the ablated tissue whereby subsequent maturation of the patient's antigen presenting cells systemically stimulate anti-tumor or anti-pathogen immunity.
generating antigens from the disease or pathogen infection in situ; and administering allogeneic cells directed to the site of the in situ generated antigens thereby creating an immune response that serves as an adjuvant to the uptake of antigens from the ablated tissue whereby subsequent maturation of the patient's antigen presenting cells systemically stimulate anti-tumor or anti-pathogen immunity.
12. The method of claim 11 further comprising:
administering to the patient a priming composition prior to the generation of antigens in situ, the priming composition comprising allogeneic T-cells to be rejected by the patient's immune system in a manner that induces an allogeneic Th1 immunity ; and permitting the patient's immune system to form anti-allogeneic Th1 immune memory prior to the generation of in situ antigens.
administering to the patient a priming composition prior to the generation of antigens in situ, the priming composition comprising allogeneic T-cells to be rejected by the patient's immune system in a manner that induces an allogeneic Th1 immunity ; and permitting the patient's immune system to form anti-allogeneic Th1 immune memory prior to the generation of in situ antigens.
13. The method of claim 11 wherein the antigens are generated in situ by ablation of the tumor or pathogen infected tissue.
14. The method of claim 13 wherein the ablation is by cryoablation.
15. The method of claim 13 wherein the ablation is by electroporation.
16. The method of claim 11 wherein the antigens comprise tumor or pathogen antigens, heat shock proteins and combinations thereof.
17. The method of claim 11 wherein the allogeneic cells are allogeneic T-cells.
18. The method of claim 11 wherein the allogeneic cells express high levels of Type 1 cytokines.
19. The method of claim 11 wherein the allogeneic cells express a high density of CD40L, TRAIL, FasL and combinations thereof on the cell surface.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/796,171 | 2013-03-12 | ||
| US13/796,171 US9320794B2 (en) | 2006-11-13 | 2013-03-12 | Ablative immunotherapy |
| PCT/US2014/022287 WO2014164396A1 (en) | 2013-03-12 | 2014-03-10 | Ablative immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2904853A1 true CA2904853A1 (en) | 2014-10-09 |
Family
ID=51658863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2904853A Abandoned CA2904853A1 (en) | 2013-03-12 | 2014-03-10 | Ablative immunotherapy |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2970910A4 (en) |
| JP (1) | JP6538647B2 (en) |
| KR (1) | KR102265276B1 (en) |
| CN (2) | CN106581673A (en) |
| AU (2) | AU2014249374A1 (en) |
| BR (1) | BR112015022974A8 (en) |
| CA (1) | CA2904853A1 (en) |
| IL (1) | IL241326B (en) |
| PH (1) | PH12015502086A1 (en) |
| SG (2) | SG10201707446PA (en) |
| WO (1) | WO2014164396A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110151309B (en) * | 2018-02-14 | 2022-02-15 | 上海美杰医疗科技有限公司 | Preoperative planning method and equipment for multi-modal ablation therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277368B1 (en) * | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| CN1806849A (en) * | 2005-01-19 | 2006-07-26 | 上海三维生物技术有限公司 | Method of treating tumors |
| US20080112963A1 (en) * | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
| US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| WO2009095033A1 (en) * | 2008-01-31 | 2009-08-06 | Agirx Limited | Vaccine compositons |
-
2014
- 2014-03-10 KR KR1020157028277A patent/KR102265276B1/en active IP Right Grant
- 2014-03-10 AU AU2014249374A patent/AU2014249374A1/en not_active Abandoned
- 2014-03-10 CN CN201710016168.5A patent/CN106581673A/en active Pending
- 2014-03-10 CA CA2904853A patent/CA2904853A1/en not_active Abandoned
- 2014-03-10 JP JP2016500938A patent/JP6538647B2/en active Active
- 2014-03-10 BR BR112015022974A patent/BR112015022974A8/en not_active Application Discontinuation
- 2014-03-10 WO PCT/US2014/022287 patent/WO2014164396A1/en active Application Filing
- 2014-03-10 EP EP14779681.7A patent/EP2970910A4/en not_active Ceased
- 2014-03-10 CN CN201480014494.7A patent/CN105102613A/en active Pending
- 2014-03-10 SG SG10201707446PA patent/SG10201707446PA/en unknown
- 2014-03-10 SG SG11201507350WA patent/SG11201507350WA/en unknown
-
2015
- 2015-09-08 IL IL241326A patent/IL241326B/en active IP Right Grant
- 2015-09-11 PH PH12015502086A patent/PH12015502086A1/en unknown
-
2020
- 2020-02-21 AU AU2020201309A patent/AU2020201309A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201707446PA (en) | 2017-10-30 |
| BR112015022974A2 (en) | 2017-07-18 |
| CN105102613A (en) | 2015-11-25 |
| EP2970910A4 (en) | 2016-11-16 |
| CN106581673A (en) | 2017-04-26 |
| IL241326A0 (en) | 2015-11-30 |
| PH12015502086A1 (en) | 2016-01-18 |
| KR102265276B1 (en) | 2021-06-16 |
| KR20150138234A (en) | 2015-12-09 |
| BR112015022974A8 (en) | 2019-11-26 |
| AU2014249374A1 (en) | 2015-09-24 |
| WO2014164396A1 (en) | 2014-10-09 |
| EP2970910A1 (en) | 2016-01-20 |
| JP2016518319A (en) | 2016-06-23 |
| AU2020201309A1 (en) | 2020-03-12 |
| JP6538647B2 (en) | 2019-07-03 |
| SG11201507350WA (en) | 2015-10-29 |
| IL241326B (en) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11213576B2 (en) | Vaccine comprising allogeneic T-cells | |
| JP6278597B2 (en) | Methods and compositions for tumor clearing | |
| US20160243231A1 (en) | Ablative Immunotherapy | |
| KR20140097419A (en) | Immunogenic treatment of cancer | |
| US20080112963A1 (en) | Ablative immunotherapy | |
| JP6789913B2 (en) | Th1 vaccination priming for active immunotherapy | |
| AU2020201309A1 (en) | Ablative immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190226 |
|
| FZDE | Discontinued |
Effective date: 20220525 |
|
| FZDE | Discontinued |
Effective date: 20220525 |